[HTML][HTML] Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant

…, T Lambe, M Laubscher, M Malahleha… - … England Journal of …, 2021 - Mass Medical Soc
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

[HTML][HTML] Preexposure prophylaxis for HIV infection among African women

…, J Lombaard, S Kapiga, M Malahleha… - … England Journal of …, 2012 - Mass Medical Soc
Background Preexposure prophylaxis with antiretroviral drugs has been effective in the
prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. …

[HTML][HTML] Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

…, JC Innes, M Lempicki, M Malahleha… - … England Journal of …, 2019 - Mass Medical Soc
Background Results of an earlier analysis of a trial of the M72/AS01 E candidate vaccine
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% …

[HTML][HTML] Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

…, MA Demoitié, M Tameris, M Malahleha… - … England Journal of …, 2018 - Mass Medical Soc
Background A vaccine to interrupt the transmission of tuberculosis is needed. Methods We
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E …

[HTML][HTML] Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults

…, LG Bekker, F Laher, M Malahleha… - … England Journal of …, 2021 - Mass Medical Soc
Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/…

[HTML][HTML] Risk factors associated with HIV acquisition in males participating in HIV vaccine efficacy trials in South Africa

M Malahleha, F Laher, A Dilraj, P Smith, GE Gray… - AIDS and Behavior, 2023 - Springer
In South Africa, HIV acquisition risk has been studied less in people assigned male at birth.
We studied the associations between risk behaviors, clinical features and HIV incidence …

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa

…, A Jose, T Lambe, M Laubscher, M Malahleha… - MedRxiv, 2021 - medrxiv.org
Background Assessing safety and efficacy of Covid-19 vaccines in different populations is
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …

[HTML][HTML] Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

…, GD Tomaras, KW Cohen, M Allen, M Malahleha… - The lancet HIV, 2018 - thelancet.com
Background Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which
comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These …

[HTML][HTML] Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials

…, ADM Kashuba, C Parker, A Lemons, M Malahleha… - AIDS and Behavior, 2015 - Springer
Oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) has been evaluated as pre-exposure
prophylaxis (PrEP). We describe the accuracy of self-reported adherence to FTC/TDF …

[HTML][HTML] C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial

…, ST Hoff, B Borregaard, E Hellstrom, M Malahleha… - PLoS …, 2018 - journals.plos.org
Background C-Tb, an ESAT-6/CFP-10-based skin test, has similar sensitivity for active TB
compared to tuberculin skin test (TST) and QuantiFERON-TB-Gold-In-Tube (QFT). However, …